{"id":605,"date":"2026-01-28T11:18:38","date_gmt":"2026-01-28T10:18:38","guid":{"rendered":"https:\/\/studienportal-gyn.de\/news-for-patients-with-platinum-resistant-ovarian-cancer\/"},"modified":"2026-03-05T16:49:15","modified_gmt":"2026-03-05T15:49:15","slug":"news-for-patients-with-platinum-resistant-ovarian-cancer","status":"publish","type":"post","link":"https:\/\/studienportal-gyn.de\/en\/news-for-patients-with-platinum-resistant-ovarian-cancer\/","title":{"rendered":"News for patients with platinum-resistant ovarian cancer"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

News for patients<\/strong> with platinum-resistant ovarian cancer<\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

The pharmaceutical company Eli Lilly<\/b><\/span> recently received approval from the US Food and Drug Administration<\/b><\/span> with a Breakthrough Therapy Designation<\/i> for a new drug called sofetabart mipitecan<\/b><\/span> was awarded. This designation is only awarded if an active substance shows initial indications that it could deliver significantly better results in a serious disease than previously available therapies. <\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

What is Sofetabart mipitecan?<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Sofetabart mipitecan<\/i> is a so-called antibody-drug conjugate (ADC)<\/b><\/span> that specifically targets the folic acid receptor alpha (FR\u03b1)<\/b><\/span> on tumor cells and releases a chemotherapy substance there. This receptor is strongly present in many ovarian tumors, which should allow the drug to have a targeted effect.
Previous results from early studies, which were presented at major cancer congresses such as ASCO 2025 and ESMO 2025, showed a tumor response in patients<\/b><\/span>who had previously received standard therapies such as bevacizumab<\/i> or mirvetuximab soravtansine<\/i>. The data to date also indicate that side effects are manageable<\/b><\/span> and that severe lung problems, nerve damage or severe eye damage <\/b>rarely occurred.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

What does the FDA designation mean?<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

The Breakthrough Therapy Designation<\/i> is intended to accelerate the development process<\/b><\/span> and enable earlier discussions with authorities. Although it is not a sure indication of approval, it does mean that the results to date are so promising that faster development and testing seems sensible. <\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Phase 3 study FRAmework-01 to start soon in Germany!<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Based on these positive interim results, Lilly has initiated the Phase 3 study called FRAmework-01<\/b><\/span> has been started. In this trial, sofetabart mipitecan<\/i> is being investigated in patients with platinum-resistant ovarian cancer (PROC) as a single therapy<\/b><\/span> patients with platinum-sensitive ovarian cancer (PSOC) in combination with bevacizumab<\/i>.
The start of the trial in Germany is planned for spring 2026. spring 2026<\/b><\/span> and offers patients the opportunity to participate in an ongoing Phase 3 trial, provided they meet the inclusion criteria (e.g. diagnosis of a platinum-sensitive or platinum-resistant tumor). <\/p>

Sofetabart mipitecan<\/i> is a promising drug that could be effective in difficult-to-treat, platinum-resistant ovarian cancer, especially in tumors that no longer respond to other treatments, and is therefore a potential new therapeutic option.
The new Phase 3 FRAmework-01 trial offers the opportunity to participate in an international trial in Germany. the chance to participate in an international trial in Germany<\/b><\/span>before approval is granted at a later date. As soon as the study starts, you will find further information on our study portal! <\/p>

Source: <\/strong><\/span>Press release from Lilly<\/a> (the article is in English)<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

News for patients with platinum-resistant ovarian cancer The pharmaceutical company Eli Lilly recently received approval from the US Food and Drug Administration with a Breakthrough Therapy Designation for a new drug called sofetabart mipitecan was awarded. This designation is only awarded if an active substance shows initial indications that it could deliver significantly better results […]<\/p>\n","protected":false},"author":3,"featured_media":599,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[53,54],"tags":[67,56,66,57],"class_list":["post-605","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-studies","tag-news","tag-ovarian-cancer","tag-platinum-resistant-ovarian-cancer","tag-study"],"acf":[],"_links":{"self":[{"href":"https:\/\/studienportal-gyn.de\/en\/wp-json\/wp\/v2\/posts\/605","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/studienportal-gyn.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/studienportal-gyn.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/studienportal-gyn.de\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/studienportal-gyn.de\/en\/wp-json\/wp\/v2\/comments?post=605"}],"version-history":[{"count":1,"href":"https:\/\/studienportal-gyn.de\/en\/wp-json\/wp\/v2\/posts\/605\/revisions"}],"predecessor-version":[{"id":606,"href":"https:\/\/studienportal-gyn.de\/en\/wp-json\/wp\/v2\/posts\/605\/revisions\/606"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/studienportal-gyn.de\/en\/wp-json\/wp\/v2\/media\/599"}],"wp:attachment":[{"href":"https:\/\/studienportal-gyn.de\/en\/wp-json\/wp\/v2\/media?parent=605"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/studienportal-gyn.de\/en\/wp-json\/wp\/v2\/categories?post=605"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/studienportal-gyn.de\/en\/wp-json\/wp\/v2\/tags?post=605"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}